AKTX - Akari Therapeutics Plc
Previous close
0.99
0 0%
Share volume: 538
Last Updated: Thu 26 Dec 2024 08:29:33 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
-0.11%
PREVIOUS CLOSE
CHG
CHG%
$0.99
0.00
0.00%
Fundamental analysis
25%
Profitability
25%
Dept financing
22%
Liquidity
28%
Performance
25%
Performance
5 Days
3.16%
1 Month
-14.04%
3 Months
-67.87%
6 Months
-63.97%
1 Year
-67.44%
2 Year
-89.11%
Key data
Stock price
$0.99
DAY RANGE
$0.99 - $1.01
52 WEEK RANGE
$1.01 - $4.40
52 WEEK CHANGE
-$67.33
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
Company detail
CEO: Rachelle Jacques
Region: US
Website: akaritx.com
Employees: 9
IPO year: -
Issue type: American Depository Receipt (ADR’s)
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: akaritx.com
Employees: 9
IPO year: -
Issue type: American Depository Receipt (ADR’s)
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Akari Therapeutics, Plc focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities.
Recent news